BLyS and April serum levels in patients with autoimmune thyroid diseases

Autoimmunity Reviews

Volumn 9, Issue 3, 2010, Pages 165-169

  Fabris, M ^a   Grimaldi, F ^a   Villalta, D ^b   Picierno, A ^a   Fabro, C ^a   Bolzan, M ^a   De Vita, S ^a   Tonutti, E ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b Pordenone Hospital   (Italy)

Author keywords

April; Autoimmune thyroid disease; Autoimmunity; BLyS; Lymphoma

Indexed keywords

APRIL PROTEIN; AUTOANTIBODY; B CELL ACTIVATING FACTOR; LEVOTHYROXINE; LIGAND; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AUTOIMMUNITY; BLOOD DONOR; BLOOD LEVEL; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REVIEW; THYROID DISEASE; UPREGULATION;

B-CELL ACTIVATING FACTOR; DOWN-REGULATION; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; MALE; MIDDLE AGED; THYROIDITIS, AUTOIMMUNE; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; UP-REGULATION;

EID: 72149132837     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.07.005     Document Type: Review

References (40)

1. Caturegli P., Kimura H., Rocchi R., and Rose N.R. Autoimmune thyroid diseases. Curr Opin Rheumatol 19 1 (2007) 44-48
2. Tomer Y., and Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmunity 32 (2009) 231-239
3. Guarneri F., and Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes 14 5 (2007) 398-409
4. Jacobson E.M., and Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun 28 2-3 (2007) 85-98
5. Jacobson E.M., Huber A., and Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 30 1-2 (2008) 58-62
6. Ch'ng C.L., Jones M.K., and Kingham J.G. Celiac disease and autoimmune thyroid disease. Clin Med Res 5 3 (2007) 184-192
7. Mellemkjaer L., Pfeiffer R.M., Engels E.A., Gridley G., Wheeler W., Hemminki K., et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum 58 3 (2008) 657-666
8. Daridon C., Youinou P., and Pers J.O. BAFF, APRIL, TWE-PRIL: who's who?. Autoimmun Rev. 7 4 (2008) 267-271
9. Do R.K., Hatada E., Lee H., Tourigny M.R., Hilbert D., and Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192 7 (2000) 953-964
10. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97 1 (2001) 198-204
11. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., and Tschopp J. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192 10 (2000) 1453-1466
12. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3 9 (2002) 822-829
13. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., and Schneider P. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 11 (1999) 1697-1710
14. Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep 4 4 (2002) 345-350
15. Seyler T.M., Park Y.W., Takemura S., Bram R.J., Kurtin P.J., Goronzy J.J., et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 115 11 (2005) 3083-3092
16. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62 2 (2003) 168-171
17. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., and Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54 1 (2006) 192-201
18. Fabris M., Quartuccio L., Sacco S., De Marchi G., Pozzato G., Mazzaro C., et al. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 46 1 (2007) 37-43
19. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201 2 (2005) 195-200
20. Fabris M., Visentini D., De Re V., Picierno A., Maieron R., Cannizzaro R., et al. Elevated B cell-activating factor of the TNF family in celiac disease. Scan J Gastroentherol 42 12 (2007) 1434-1439
21. Krystufková O., Vallerskog T., Helmers S.B., Mann H., Putová I., Belácek J., et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 68 6 (2009) 836-843
22. Matsushita T., Fujimoto M., Echigo T., Matsushita Y., Shimada Y., Hasegawa M., et al. Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis. Exp Dermatol 17 3 (2008) 197-202
23. Tangye S.G., Bryant V.L., Cuss A.K., and Good K.L. BAFF, APRIL and human B cell disorders. Semin Immunol 18 5 (2006) 305-317
24. He B., Chadburn A., Jou E., Schattner E.J., Knowles D.M., and Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 172 5 (2004) 3268-3279
25. Gilbert J.A., Kalled S.L., Moorhead J., Hess D.M., Rennert P., Li Z., et al. Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology 147 10 (2006) 4561-4568
26. Guclu F., Ozmen B., Kirmaz C., Kafesciler S.O., Degirmenci P.B., Taneli F., et al. Down-regulation of the auto-aggressive processes in patients with hypothyroid Hashimoto's thyroiditis following substitutive treatment with L-thyroxine. Eur Cytokine Netw 20 1 (2008) 27-32
27. Salvi M., Pedrazzoni M., Girasole G., Giuliani N., Minelli R., Wall J.R., et al. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 143 2 (2000) 197-202
28. Szyper-Kravitz M., Marai I., and Shoenfeld Y. Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. Autoimmunity 38 3 (2005) 247-255
29. Sinclair D. Clinical and laboratory aspects of thyroid autoantibodies. Ann Clin Biochem 43 Pt 3 (2006) 173-183
30. Nakamura H., Usa T., Motomura M., Ichikawa T., Nakao K., Kawasaki E., et al. Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest 31 10 (2008) 861-865
31. Michalek K., Morshed S.A., Latif R., and Davies T.F. TSH receptor autoantibodies. Autoimmun Rev (Mar 27 2009) 10.1016/j.autrev.2009.03.012
32. Stagi S., Azzari C., Bindi G., Galluzzi F., Nanni S., Salti R., et al. Undetectable serum IgA and low IgM concentration in children with congenital hypothyroidism. Clin Immunol 116 1 (2005) 94-98
33. Kim H., Lee T.H., Hwang Y.S., Bang M.A., Kim K.H., Suh J.M., et al. Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging. Mol Pharmacol 60 5 (2001) 972-980
34. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther 8 11 (2008) 1805-1814
35. Zekavat G., Rostami S.Y., Badkerhanian A., Parsons R.F., Koeberlein B., Yu M., et al. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol 181 11 (2008) 8133-8144
36. Rodien P. Rituximab in Graves' disease. Eur J Endocrinol 159 5 (2008) 515-516
37. El Fassi D., Banga J.P., Gilbert J.A., Padoa C., Hegedüs L., and Nielsen C.H. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130 3 (2009) 252-258
38. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., and Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 66 5 (2007) 700-703
39. Quartuccio L., Fabris M., Moretti M., Barone F., Bombardieri M., Rupolo M., et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2 (2008) 38-43
40. Dörner T., and Burmester G.R. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 20 3 (2008) 263-268